Exploring the Feasibility of Telerehabilitation for Balance Deficits in People with PD; the TelePD Trial
Objective: To evaluate the feasibility of adapting our Agility Boot Camp (ABC) for balance telerehabilitation (Tele-ABC) in people with mild-to-moderate Parkinson’s disease (PD). Background: Balance impairments…Hand and Arm Function in Persons with De Novo Parkinson’s Disease
Objective: To evaluate hand and arm function and its association with motor symptoms as well as activities of daily living (ADL) in de novo Parkinson's…Does cannabis increase one’s risk for a fall in Parkinson’s disease?: cross-sectional analysis of self-report balance problems and freezing of gait
Objective: To explore the effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on self-report balance problems and freezing of gait (FOG) in Parkinson's disease (PD). Background:…Perceptions of Diseases in Patients with Cervical Dystonia
Objective: To explore how perception of disease can impact stigma, mood, quality of life, and severity of symptoms in patients with cervical dystonia (CD). Background:…‘If you can’t beat them, join them’: a patient and family perspective on quality of life with North Sea progressive myoclonus epilepsy
Objective: To describe the perspectives of patients and their family on quality of life (QoL) in North Sea- Progressive Myoclonus Epilepsy (NS-PME). Background: NS-PME is…Lumbar Punctures in Parkinson’s Research
Objective: This study aims to explore patient perspectives on lumbar punctures for cerebrospinal fluid (CSF) analysis in Parkinson’s disease (PD) research, with the objective of…Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update
Objective: To provide an update on the baseline demographics and safety from the HORIZON Clinical Trial of ION464 Background: Multiple System Atrophy (MSA) is a…Coordinated Reset Vibrotactile Therapy for the Treatment of Bradykinesia in Parkinson’s Disease Patients
Objective: The present research examines a novel non-invasive vibrotactile device for stimulation of fingertips in a pattern that aims to disrupt pathological physiological beta-band oscillations…Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease
Objective: The Korean and European ADOPTION studies aimed to explore the efficacy of opicapone (OPC) 50 mg versus an additional 100 mg levodopa dose to…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.